Loading...
XNYS
GKOS
Market cap5.48bUSD
May 19, Last price  
95.85USD
1D
0.40%
1Q
-37.34%
Jan 2017
179.45%
IPO
242.32%
Name

Glaukos Corp

Chart & Performance

D1W1MN
P/E
—
P/S
14.28
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.10%
Rev. gr., 5y
10.10%
Revenues
383m
+21.85%
2,429,00020,946,00045,587,00071,700,000114,397,000159,254,000181,278,000236,984,000224,959,000294,011,000282,862,000314,711,000383,481,000
Net income
-146m
L+8.70%
-19,331,000-12,639,000-12,126,000-37,241,0004,522,000-92,000-12,951,00015,424,000-120,348,000-49,593,000-99,195,000-134,661,000-146,372,000
CFO
-61m
L+6.16%
-20,455,000-13,305,000-7,107,000-2,188,00012,309,00025,508,00018,864,000-369,000-22,988,00024,708,000-33,083,000-57,758,000-61,318,000
Earnings
Jul 29, 2025

Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
URL
https://www.glaukos.com
IPO date
Jun 25, 2015
Employees
783
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
383,481
21.85%
314,711
11.26%
282,862
-3.79%
Cost of revenue
230,452
438,411
385,175
Unusual Expense (Income)
NOPBT
153,029
(123,700)
(102,313)
NOPBT Margin
39.91%
Operating Taxes
771
934
766
Tax Rate
0.50%
NOPAT
152,258
(124,634)
(103,079)
Net income
(146,372)
8.70%
(134,661)
35.75%
(99,195)
100.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
231,676
(3,273)
6,477
BB yield
-2.93%
0.09%
-0.31%
Debt
Debt current
430
Long-term debt
206,798
484,703
483,554
Deferred revenue
Other long-term liabilities
22,373
13,752
10,278
Net debt
(112,117)
189,272
124,211
Cash flow
Cash from operating activities
(61,318)
(57,758)
(33,083)
CAPEX
(6,300)
(20,248)
(30,265)
Cash from investing activities
47,831
14,095
44,779
Cash from financing activities
91,540
15,042
6,251
FCF
127,123
(139,123)
(133,286)
Balance
Cash
318,915
295,431
352,695
Long term investments
7,078
Excess cash
299,741
279,695
345,630
Stockholders' equity
(742,768)
(597,853)
(467,333)
Invested Capital
1,635,471
1,457,109
1,390,523
ROIC
9.85%
ROCE
17.01%
EV
Common stock shares outstanding
52,755
48,433
47,444
Price
149.94
88.63%
79.49
81.98%
43.68
-1.71%
Market cap
7,910,085
105.46%
3,849,939
85.78%
2,072,354
0.45%
EV
7,797,968
4,039,211
2,196,565
EBITDA
188,679
(85,722)
(66,367)
EV/EBITDA
41.33
Interest
10,040
13,633
13,720
Interest/NOPBT
6.56%